Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Analysts have struggled to estimate the size of the compounded market for weight-loss drugs because their sale is not tracked in traditional channels.
Diabetes and weight loss drugs shown to reduce alcohol-related hospitalizations, study finds
Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why diabetes and weight loss drugs work better than alcohol medications.
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease,
NJBIZ3h
Pharma giants defend against high-stakes lawsuit over weight loss drugs
Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...
5 new weight-loss drugs to watch in the fight for the next Ozempic
Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...
Should You Forget Eli Lilly and Buy This Magnificent Biotech Stock Instead?
Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...
The Motley Fool4d
Did Viking Therapeutics Just Say "Checkmate" To Eli Lilly?
Right now, Eli Lilly dominates the weight loss industry thanks to its dual agonists Mounjaro and Zepbound. Viking ...
tyla5d
Company behind weight loss drug Mounjaro issues statement as first Brit dies after using jab twice
Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...
Goldman Sachs Economist: Weight-Loss Drugs Could Be Key To US Economic Growth
A Goldman Sachs economist has suggested that the US economy could experience accelerated growth with increased use of GLP-1 ...
Is AstraZeneca a Buy as It Eyes the Weight Loss Market?
The chart below compares the forward price to earnings (P/E) ratio of AstraZeneca to multiples in a peer set of leading ...
Seeking Alpha13d
How does Viking's weight loss med compare to ones from Novo, Eli Lilly?
Data reported earlier Monday from Viking Therapeutics (NASDAQ:VKTX) on its weight loss medicine VK2735 indicates that Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY), which currently dominate the ...